Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


Using Bayesian Adaptive Trial Designs for Comparative Effectiveness Research: A Virtual Trial Execution.

Luce BR, Connor JT, Broglio KR, Mullins CD, Ishak KJ, Saunders E, Davis BR; RE-ADAPT (REsearch in ADAptive methods for Pragmatic Trials) Investigators.

Ann Intern Med. 2016 Sep 20;165(6):431-8. doi: 10.7326/M15-0823. Epub 2016 Jun 7.


Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.

Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D, Berry DA.

JAMA Oncol. 2016 Jun 1;2(6):751-60. doi: 10.1001/jamaoncol.2015.6113.


Bayesian dose escalation in oncology with sharing of information between patient populations.

Broglio KR, Sandalic L, Albertson T, Berry SM.

Contemp Clin Trials. 2015 Sep;44:56-63. doi: 10.1016/j.cct.2015.07.003. Epub 2015 Jul 11.


The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial: an adaptive trial design case study.

Connor JT, Broglio KR, Durkalski V, Meurer WJ, Johnston KC.

Trials. 2015 Mar 4;16:72. doi: 10.1186/s13063-015-0574-8.


A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

Broglio KR, Daar ES, Quintana M, Yuan Y, Kalsekar A, Spellberg B, Lewis RJ, Akker Dv, Detry MA, Le T, Berry SM.

J Comp Eff Res. 2015 Mar;4(2):101-14. doi: 10.2217/cer.14.69. Review.


Not too big, not too small: a goldilocks approach to sample size selection.

Broglio KR, Connor JT, Berry SM.

J Biopharm Stat. 2014;24(3):685-705. doi: 10.1080/10543406.2014.888569.


Predicting clinical trial results based on announcements of interim analyses.

Broglio KR, Stivers DN, Berry DA.

Trials. 2014 Mar 7;15:73. doi: 10.1186/1745-6215-15-73.


Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study.

Connor JT, Luce BR, Broglio KR, Ishak KJ, Mullins CD, Vanness DJ, Fleurence R, Saunders E, Davis BR.

Clin Trials. 2013 Oct;10(5):807-27. doi: 10.1177/1740774513497293. Epub 2013 Aug 27.


Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials.

Berry SM, Broglio KR, Groshen S, Berry DA.

Clin Trials. 2013 Oct;10(5):720-34. doi: 10.1177/1740774513497539. Epub 2013 Aug 27.


Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.

Connor JT, Elm JJ, Broglio KR; ESETT and ADAPT-IT Investigators.

J Clin Epidemiol. 2013 Aug;66(8 Suppl):S130-7. doi: 10.1016/j.jclinepi.2013.02.015.


Combining risk difference and risk ratio in noninferiority trials of safety.

Broglio KR, Connor JT, Berry SM.

J Biopharm Stat. 2013;23(1):261-71. doi: 10.1080/10543406.2011.616966.


Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer.

Durak MG, Gonzalez-Angulo AM, Hanrahan EO, Broglio KR, Valero V, Hortobagyi GN, Hunt KK, Sahin AA.

Breast J. 2011 Sep-Oct;17(5):462-9. doi: 10.1111/j.1524-4741.2011.01116.x. Epub 2011 Jul 5.


Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis.

Berry SM, Broglio KR, Berry DA.

Cancer Invest. 2011 May;29(4):293-9. doi: 10.3109/07357907.2011.568563.


Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.

Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE.

Kidney Int. 2010 Aug;78(3):303-9. doi: 10.1038/ki.2010.129. Epub 2010 May 5.


Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer.

Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, Jackson SA, Ueno NT, Krishnamurthy S, Hortobagyi GN, Cristofanilli M.

Breast J. 2010 May-Jun;16(3):327-30. doi: 10.1111/j.1524-4741.2010.00910.x. Epub 2010 Apr 12. No abstract available.


Detecting an overall survival benefit that is derived from progression-free survival.

Broglio KR, Berry DA.

J Natl Cancer Inst. 2009 Dec 2;101(23):1642-9. doi: 10.1093/jnci/djp369. Epub 2009 Nov 9.


High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN.

J Clin Oncol. 2009 Dec 1;27(34):5700-6. doi: 10.1200/JCO.2009.23.2025. Epub 2009 Nov 2.


Effects of chronic hepatitis C infection on the treatment of breast cancer patients.

Morrow PK, Tarrand JJ, Taylor SH, Kau SW, Theriault RL, Hortobagyi GN, Broglio KR, Hahn KM.

Ann Oncol. 2010 Jun;21(6):1233-6. doi: 10.1093/annonc/mdp458. Epub 2009 Oct 29.


Scientific writing training for academic physicians of diverse language backgrounds.

Cameron C, Deming SP, Notzon B, Cantor SB, Broglio KR, Pagel W.

Acad Med. 2009 Apr;84(4):505-10. doi: 10.1097/ACM.0b013e31819a7e6d.


High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers.

Arun B, Vogel KJ, Lopez A, Hernandez M, Atchley D, Broglio KR, Amos CI, Meric-Bernstam F, Kuerer H, Hortobagyi GN, Albarracin CT.

Cancer Prev Res (Phila). 2009 Feb;2(2):122-7. doi: 10.1158/1940-6207.CAPR-08-0050. Epub 2009 Jan 27.


Accuracy of the BRCAPRO model among women with bilateral breast cancer.

Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, Lu KH, Hortobagyi GN, Arun B.

Cancer. 2009 Feb 15;115(4):725-30. doi: 10.1002/cncr.24102.


Residual risk of breast cancer recurrence 5 years after adjuvant therapy.

Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ.

J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83. doi: 10.1093/jnci/djn233. Epub 2008 Aug 11.


Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.

Jeruss JS, Newman LA, Ayers GD, Cristofanilli M, Broglio KR, Meric-Bernstam F, Yi M, Waljee JF, Ross MI, Hunt KK.

Cancer. 2008 Jun 15;112(12):2646-54. doi: 10.1002/cncr.23481.


Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.

Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V.

Cancer. 2008 Apr 1;112(7):1455-61. doi: 10.1002/cncr.23321.


Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.

Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V.

J Clin Oncol. 2007 Nov 1;25(31):4952-60.


Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation.

Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA, Safdar A, Broglio KR, Adachi R, Dickey BF.

Bone Marrow Transplant. 2008 Jan;41(1):63-7. Epub 2007 Oct 15.


BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.

Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, Lu KH, Arun B.

J Clin Oncol. 2007 Oct 10;25(29):4635-41.


Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.

Cristofanilli M, Valero V, Buzdar AU, Kau SW, Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R, Ueno NT, Buchholz TA, Singletary SE, Hortobagyi GN.

Cancer. 2007 Oct 1;110(7):1436-44.


Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden.

Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, Dawood S, Reuben JM, Kau SW, Lara JM, Krishnamurthy S, Ueno NT, Hortobagyi GN, Valero V.

Clin Breast Cancer. 2007 Feb;7(6):471-9.


Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer.

Cabioglu N, Gong Y, Islam R, Broglio KR, Sneige N, Sahin A, Gonzalez-Angulo AM, Morandi P, Bucana C, Hortobagyi GN, Cristofanilli M.

Ann Oncol. 2007 Jun;18(6):1021-9. Epub 2007 Mar 9.


Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).

Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM.

Breast J. 2007 Jan-Feb;13(1):72-5.


Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.

Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN.

Clin Cancer Res. 2007 Jan 1;13(1):228-33.


Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

Yang CH, Gonzalez-Angulo AM, Reuben JM, Booser DJ, Pusztai L, Krishnamurthy S, Esseltine D, Stec J, Broglio KR, Islam R, Hortobagyi GN, Cristofanilli M.

Ann Oncol. 2006 May;17(5):813-7. Epub 2006 Jan 10.


High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF.

J Clin Oncol. 2005 Oct 1;23(28):7013-23. Epub 2005 Sep 6. Erratum in: J Clin Oncol. 2006 Feb 1;24(4):724.


CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.

Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE, Sahin A.

Clin Cancer Res. 2005 Aug 15;11(16):5686-93.


Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.

Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, Yin G, Kau SW, Hortobagyi GN, Rivera E.

Cancer. 2005 Sep 15;104(6):1158-71.


Adult glioma incidence trends in the United States, 1977-2000.

Hess KR, Broglio KR, Bondy ML.

Cancer. 2004 Nov 15;101(10):2293-9.


Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.

Gonzalez-Angulo AM, Cristofanilli M, Strom EA, Buzdar AU, Kau SW, Broglio KR, Smith TL, Hortobagyi GN.

Cancer. 2004 Oct 15;101(8):1760-6.


Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.

Gonzalez-Angulo AM, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ.

Cancer. 2004 Jul 15;101(2):258-63.


Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA.

Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7.


A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050.

Honeycutt AA, Boyle JP, Broglio KR, Thompson TJ, Hoerger TJ, Geiss LS, Narayan KM.

Health Care Manag Sci. 2003 Aug;6(3):155-64.


Supplemental Content

Loading ...
Support Center